Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

Journal Browser

Bridging the Gap between the Clinical and Regulatory Use of Plasma Rich in Growth Factors. Where Are We?

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Benefits of Publishing in a Special Issue
Published Papers

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 9099

Share This Special Issue

Special Issue Editors

Dr. Eduardo Anitua

E-Mail Website
Guest Editor

Department Head, Eduardo Anitua Foundation, Vitoria; Private Practice in Oral Implantology, Vitoria, Spain
Interests: regenerative medicine; plasma rich in growth factors; PRGF; growth factors; cell therapy; evidence-based clinical practice; implant dentistry

Dr. Mohammad Hamdan Alkhraisat

E-Mail Website
Guest Editor

1. Regenerative Medicine Department, BTI Biotechnology Institute, 01005 Vitoria, Spain
2. Clinical Research, University Institute for Regenerative Medicine and Oral Implantology (UIRMI), 01005 Vitoria, Spain
Interests: oral medicine; implant dentistry; biomaterials; regenerative medicine; PRGF

Dr. Sabino Padilla

E-Mail Website
Guest Editor

1. University Institute for Regenerative Medicine and OralImplantology - UIRMI (UPV/EHU-Fundación Eduardo Anitua), Vitoria, Spain
2. BTI Biotechnology Institute, Vitoria, Spain
Interests: Evolution; Coagulation; Haemostasia; Platelets: Platelet-rich plasma; Wound healing; Epigenetics; minimally-invasive surgery; Orthopaedics

Special Issue Information

Dear Colleagues,

Platelet-rich plasma (PRP) therapies have been attracting great attention in both the research and clinical community. However, the field faces important challenges at the basic, clinical, and regulatory frameworks. These three fields are progressing at a different pace, thereby generating a gap that in certain occasions is difficult to bridge effectively and efficiently. An evidence-based approach and appropriate regulatory framework would ensure both patient safety and the consolidation of current treatments and development of future applications. At the same time, quality studies are needed to promote the safe advancement of these types of biologic therapies.

Manuscripts are welcome to be submitted to cover the topics of platelet-rich plasma therapies, including in vitro research, preclinical in vivo, clinical studies or regulatory issues regarding the use of PRPs. However, the topics of interest are not limited to these. This issue aims to put in the same space and time coordinated basic, translational, and clinical research together with a regulatory/ethical overview in an effort to approximate the needs and bridge the gap.

Dr. Eduardo Anitua
Dr. Mohammad Alkhraisat
Dr. Sabino Padilla
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

Advanced cell therapy
Platelet-rich plasma
Wound healing
Stem cells
Patient care
Medicine
Platelets
Plasma
Patient screening
Blood processing

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review, Other

17 pages, 3600 KiB

Open AccessArticle

Proteomic Characterization of Plasma Rich in Growth Factors and Undiluted Autologous Serum

by Eduardo Anitua, Francisco Muruzabal, Ander Pino, Roberto Prado, Mikel Azkargorta, Felix Elortza and Jesús Merayo-Lloves

Int. J. Mol. Sci. 2021, 22(22), 12176; https://doi.org/10.3390/ijms222212176 - 10 Nov 2021

Cited by 13 | Viewed by 2352

Abstract

Over the last three decades, there has been special interest in developing drugs that mimic the characteristics of natural tears for use it in the treatment of several ocular surface disorders. Interestingly, the composition of blood plasma is very similar to tears. Therefore, different blood-derived products like autologous serum (AS) and plasma rich in growth factors (PRGF) have been developed for the treatment of diverse ocular pathologies. However, scarce studies have been carried out to analyze the differences between both types of blood-derived products. In the present study, blood from three healthy donors was drawn and processed to obtain AS and PRGF eye drops. Then, human corneal stromal keratocytes (HK) were treated with PRGF or undiluted AS. Proteomic analysis was carried out to analyze and characterize the differential protein profiles between PRGF and AS, and the differentially expressed proteins in HK cells after PRGF and AS treatment. The results obtained in the present study show that undiluted AS induces the activation of different pathways related to an inflammatory, angiogenic, oxidative stress and scarring response in HK cells regarding PRGF. These results suggest that PRGF could be a better alternative than AS for the treatment of ocular surface disorders. Full article

(This article belongs to the Special Issue Bridging the Gap between the Clinical and Regulatory Use of Plasma Rich in Growth Factors. Where Are We?)

► Show Figures

Figure 1

Review

Jump to: Research, Other

28 pages, 919 KiB

Open AccessReview

Platelet-Rich Plasma as an Alternative to Xenogeneic Sera in Cell-Based Therapies: A Need for Standardization

by Eduardo Anitua, Mar Zalduendo, Maria Troya, Mohammad H. Alkhraisat and Leticia Alejandra Blanco-Antona

Int. J. Mol. Sci. 2022, 23(12), 6552; https://doi.org/10.3390/ijms23126552 - 11 Jun 2022

Cited by 9 | Viewed by 2693

Abstract

There has been an explosion in scientific interest in using human-platelet-rich plasma (PRP) as a substitute of xenogeneic sera in cell-based therapies. However, there is a need to create standardization in this field. This systematic review is based on literature searches in PubMed and Web of Science databases until June 2021. Forty-one studies completed the selection criteria. The composition of PRP was completely reported in less than 30% of the studies. PRP has been used as PRP-derived supernatant or non-activated PRP. Two ranges could be identified for platelet concentration, the first between 0.14 × 10⁶ and 0.80 × 10⁶ platelets/µL and the second between 1.086 × 10⁶ and 10 × 10⁶ platelets/µL. Several studies have pooled PRP with a pool size varying from four to nine donors. The optimal dose for the PRP or PRP supernatant is 10%. PRP or PRP-derived supernatants a have positive effect on MSC colony number and size, cell proliferation, cell differentiation and genetic stability. The use of leukocyte-depleted PRP has been demonstrated to be a feasible alternative to xenogeneic sera. However, there is a need to improve the description of the PRP preparation methodology as well as its composition. Several items are identified and reported to create guidelines for future research. Full article

(This article belongs to the Special Issue Bridging the Gap between the Clinical and Regulatory Use of Plasma Rich in Growth Factors. Where Are We?)

► Show Figures

Figure 1

Other

Jump to: Research, Review

11 pages, 4965 KiB

Open AccessCase Report

Plasma Rich in Growth Factors in the Treatment of Endodontic Periapical Lesions in Adult Patients: Case Reports

by Katarzyna Machut, Agata Zoltowska, Elzbieta Pawlowska and Marcin Derwich

Int. J. Mol. Sci. 2021, 22(17), 9458; https://doi.org/10.3390/ijms22179458 - 31 Aug 2021

Cited by 6 | Viewed by 2959

Abstract

Platelet-rich fibrin (PRF) is an autologous blood concentrate obtained without anticoagulants by centrifugation of patients’ peripheral venous blood. PRF is considered to enhance the formation of new bone. The aim of this manuscript was to present two case reports of permanent teeth with closed apexes with periapical lesions, treated endodontically with the use of PRF. The root canals were mechanically cleaned and shaped with NiTi files and irrigated with 5.25% sodium hypochlorite (NaOCl), 40% citric acid (CA), and triple distillated water. Before the canal systems were obturated, A-PRF was used as a scaffold and was placed below the cementodentinal junction with hand pluggers. Cone beam computerized tomography (CBCT) was used to assess the resolutions of periapical radiolucencies. After 6 months, the measurements of both periapical lesions were significantly reduced. Although the performed root canal treatments (RCTs) can definitely be recognized as successful, it must be emphasized that mechanical shaping and cleaning of the root canals with special disinfecting solutions significantly affect the clinical efficacy of RCT. It seems impossible to state that PRF played a leading role in the healing process of the presented periapical lesions. Further studies must be performed to assess whether RCT of mature teeth with an additional PRF application is superior to RCT performed alone. Full article

(This article belongs to the Special Issue Bridging the Gap between the Clinical and Regulatory Use of Plasma Rich in Growth Factors. Where Are We?)

► Show Figures

Journal Menu

Journal Browser

Bridging the Gap between the Clinical and Regulatory Use of Plasma Rich in Growth Factors. Where Are We?

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (3 papers)

Research

Review

Other

Further Information

Guidelines

MDPI Initiatives

Follow MDPI